Biomarkers for Huntington's disease: An update

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 5, 2012, Pages 371-375

  Scahill, Rachael I ^a   Wild, Ed J ^b   Tabrizi, Sarah J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

biofluids; biomarkers; Huntington's disease; imaging

Indexed keywords

BIOLOGICAL MARKER; HUNTINGTIN; MUTANT PROTEIN;

AGAR GEL ELECTROPHORESIS; BLOOD ANALYSIS; BODY FLUID; CAG REPEAT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DIFFUSION WEIGHTED IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUNCTIONAL ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; MEDLINE; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; PROTEIN PROCESSING; PUBLICATION; QUANTITATIVE ANALYSIS; REVIEW;

EID: 84865497146     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.701205     Document Type: Review

References (22)

1. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8(9):791-801
2. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79(8):874-80
3. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10(1):31-42
4. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11(1):42-53
5. Weaver KE, Richards TL, Liang O, et al. Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol 2009;216(2):525-9
6. Sritharan A, Egan GF, Johnston L, et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry 2010;81(3):257-62
7. Kloppel S, Draganski B, Siebner HR, et al. Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain 2009;132(Pt 6):1624-32
8. Wolf RC, Sambataro F, Vasic N, et al. Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Exp Neurol 2011;231(2):214-22
9. Schippling S, Schneider SA, Bhatia KP, et al. Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol Psychiatry 2009;65(11):959-65
10. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol 2011;10(6):573-90
11. Rowe KC, Paulsen JS, Langbehn DR, et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010;24(4):435-42
12. Beglinger LJ, Duff K, Allison J, et al. Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status. J Clin Exp Neuropsychol 2010;32(6):573-8
13. Leoni V, Mariotti C, Tabrizi SJ, et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008;131(Pt 11):2851-9
14. Hu Y, Chopra V, Chopra R, et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci USA 2011;108(41):17141-6
15. Dalrymple A, Wild EJ, Joubert R, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007;6(7):2833-40
16. Hardy J, Guerreiro R, Lovestone S. Clusterin as an Alzheimer biomarker. Arch Neurol 2011;68(11):1459-60
17. Weiss A, Klein C, Woodman B, et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem 2008;104(3):846-58
18. Weiss A, Abramowski D, Bibel M, et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem 2009;395(1):8-15
19. Fang Q, Strand A, Law W, et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 2009;8(3):451-66
20. Constantinescu R, Romer M, Zetterberg H, et al. Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord 2011;17(9):714-15
21. Baker K, Queller S, Clough MJ, et al. The Huntington's disease (HD) Toolkit Project; using meta-analysis to identify cognitive tests for use in clinical trials. Clinical Genetics 2011. 80-S1), 47
22. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6(3):131-44